FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013683525> ?p ?o ?g. }

• W2013683525 endingPage "767" @default.
• W2013683525 startingPage "758" @default.
• W2013683525 abstract "BACKGROUND: On the basis of potential additive or synergistic immunostimulatory antitumor effects, in this phase 1 study, the authors evaluated the combination of sunitinib and tremelimumab (CP-675206; an antibody against cytotoxic T-lymphocyte–associated antigen 4 [CTLA4]) in patients with metastatic renal cell carcinoma (mRCC) was evaluated. METHODS: Adult patients with mRCC who had received ≤1 previous systemic treatment received tremelimumab (6 mg/kg, 10 mg/kg, or 15 mg/kg) intravenously once every 12 weeks and oral sunitinib (50 mg daily for 4 weeks then 2 weeks off or 37.5 mg daily as a continuous dose). The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives were to assess antitumor activity, safety, and pharmacokinetics. RESULTS: Twenty-eight patients were enrolled. Two of 5 patients who received 50 mg sunitinib plus tremelimumab 6 mg/kg experienced dose-limiting toxicities (DLTs), and no further enrollment to the combination with sunitinib 50 mg dosing was pursued. Among patients who received continuous sunitinib 37.5 mg daily, 1 of 7 patients who received tremelimumab 10 mg/kg plus sunitinib suffered a sudden death, and 3 of 6 patients who received tremelimumab 15 mg/kg plus sunitinib experienced DLTs. An expansion cohort (n = 7) was enrolled at tremelimumab 10 mg/kg plus sunitinib 37.5 mg daily; 3 of those patients experienced DLTs. Overall, rapid-onset renal failure was the most common DLT. Nine of 21 patients who were evaluable for response achieved partial responses (43%; 95% confidence interval, 22%-66%), and 4 of those responses were ongoing at the time of the current report. CONCLUSIONS: In this study of tremelimumab plus sunitinib, rapid-onset acute renal failure was observed unexpectedly, and further investigation of tremelimumab doses >6 mg/kg plus sunitinib 37.5 mg daily is not recommended. Preclinical investigation may be warranted to understand the mechanism of renal toxicity. Cancer 2011. © 2010 American Cancer Society." @default.
• W2013683525 created "2016-06-24" @default.
• W2013683525 creator A5017854234 @default.
• W2013683525 creator A5018011481 @default.
• W2013683525 creator A5025529463 @default.
• W2013683525 creator A5028215748 @default.
• W2013683525 creator A5046444872 @default.
• W2013683525 creator A5069690249 @default.
• W2013683525 creator A5071773606 @default.
• W2013683525 creator A5076174959 @default.
• W2013683525 creator A5090818778 @default.
• W2013683525 creator A5035128253 @default.
• W2013683525 date "2010-10-04" @default.
• W2013683525 modified "2023-09-26" @default.
• W2013683525 title "Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma" @default.
• W2013683525 cites W1987446429 @default.
• W2013683525 cites W1999209934 @default.
• W2013683525 cites W2056084656 @default.
• W2013683525 cites W2088571368 @default.
• W2013683525 cites W2103506609 @default.
• W2013683525 cites W2113788015 @default.
• W2013683525 cites W2129411754 @default.
• W2013683525 cites W2141579931 @default.
• W2013683525 cites W2149456801 @default.
• W2013683525 cites W2163184777 @default.
• W2013683525 doi "https://doi.org/10.1002/cncr.25639" @default.
• W2013683525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20922784" @default.
• W2013683525 hasPublicationYear "2010" @default.
• W2013683525 type Work @default.
• W2013683525 sameAs 2013683525 @default.
• W2013683525 citedByCount "141" @default.
• W2013683525 countsByYear W20136835252012 @default.
• W2013683525 countsByYear W20136835252013 @default.
• W2013683525 countsByYear W20136835252014 @default.
• W2013683525 countsByYear W20136835252015 @default.
• W2013683525 countsByYear W20136835252016 @default.
• W2013683525 countsByYear W20136835252017 @default.
• W2013683525 countsByYear W20136835252018 @default.
• W2013683525 countsByYear W20136835252019 @default.
• W2013683525 countsByYear W20136835252020 @default.
• W2013683525 countsByYear W20136835252021 @default.
• W2013683525 countsByYear W20136835252022 @default.
• W2013683525 countsByYear W20136835252023 @default.
• W2013683525 crossrefType "journal-article" @default.
• W2013683525 hasAuthorship W2013683525A5017854234 @default.
• W2013683525 hasAuthorship W2013683525A5018011481 @default.
• W2013683525 hasAuthorship W2013683525A5025529463 @default.
• W2013683525 hasAuthorship W2013683525A5028215748 @default.
• W2013683525 hasAuthorship W2013683525A5035128253 @default.
• W2013683525 hasAuthorship W2013683525A5046444872 @default.
• W2013683525 hasAuthorship W2013683525A5069690249 @default.
• W2013683525 hasAuthorship W2013683525A5071773606 @default.
• W2013683525 hasAuthorship W2013683525A5076174959 @default.
• W2013683525 hasAuthorship W2013683525A5090818778 @default.
• W2013683525 hasConcept C112705442 @default.
• W2013683525 hasConcept C121608353 @default.
• W2013683525 hasConcept C126322002 @default.
• W2013683525 hasConcept C126894567 @default.
• W2013683525 hasConcept C143998085 @default.
• W2013683525 hasConcept C2777288759 @default.
• W2013683525 hasConcept C2777472916 @default.
• W2013683525 hasConcept C2777701055 @default.
• W2013683525 hasConcept C2778650287 @default.
• W2013683525 hasConcept C2779490328 @default.
• W2013683525 hasConcept C2781433595 @default.
• W2013683525 hasConcept C71924100 @default.
• W2013683525 hasConcept C90924648 @default.
• W2013683525 hasConceptScore W2013683525C112705442 @default.
• W2013683525 hasConceptScore W2013683525C121608353 @default.
• W2013683525 hasConceptScore W2013683525C126322002 @default.
• W2013683525 hasConceptScore W2013683525C126894567 @default.
• W2013683525 hasConceptScore W2013683525C143998085 @default.
• W2013683525 hasConceptScore W2013683525C2777288759 @default.
• W2013683525 hasConceptScore W2013683525C2777472916 @default.
• W2013683525 hasConceptScore W2013683525C2777701055 @default.
• W2013683525 hasConceptScore W2013683525C2778650287 @default.
• W2013683525 hasConceptScore W2013683525C2779490328 @default.
• W2013683525 hasConceptScore W2013683525C2781433595 @default.
• W2013683525 hasConceptScore W2013683525C71924100 @default.
• W2013683525 hasConceptScore W2013683525C90924648 @default.
• W2013683525 hasIssue "4" @default.
• W2013683525 hasLocation W20136835251 @default.
• W2013683525 hasLocation W20136835252 @default.
• W2013683525 hasOpenAccess W2013683525 @default.
• W2013683525 hasPrimaryLocation W20136835251 @default.
• W2013683525 hasRelatedWork W1895933560 @default.
• W2013683525 hasRelatedWork W1983433556 @default.
• W2013683525 hasRelatedWork W2072245035 @default.
• W2013683525 hasRelatedWork W2096517981 @default.
• W2013683525 hasRelatedWork W2171237277 @default.
• W2013683525 hasRelatedWork W2322617799 @default.
• W2013683525 hasRelatedWork W2544140097 @default.
• W2013683525 hasRelatedWork W3151554875 @default.
• W2013683525 hasRelatedWork W4205243027 @default.
• W2013683525 hasRelatedWork W4205299447 @default.
• W2013683525 hasVolume "117" @default.
• W2013683525 isParatext "false" @default.
• W2013683525 isRetracted "false" @default.

• next